TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of major depressive disorder consistent with DSM-IV-TR~* current episode greater than 8 weeks in duration~* Hamilton Depression score \>/- 21~* less than 25% reduction in depression during current episode assessed by ATRQ~Exclusion Criteria:~* Axis diagnosis of other psychiatric disorders~* Experiencing hallucinations, delusions, other psychotic symptomatology~* ECT during current episode

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): IV placebo
- GLYX-13, 1 mg/kg (Type: EXPERIMENTAL): None
- GLYX-13, 5 mg/kg (Type: EXPERIMENTAL): None
- GLYX-13, 10 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to give informed consent~* Age ≥ 18 years~* HIV-1 infection documented at any time prior to study entry~* Fasting plasma triglyceride value between 200 and 1000 mg/dL on two occasions within 4 weeks~* Subjects must be receiving a stable antiretroviral medication regimen for \> 3 months without any anticipated changes during the study interval~* Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception~* On stable lipid modification pharmacotherapy for at least 8 weeks prior to study entry~Exclusion Criteria~* Hemoglobin A1C \> 8.5 %~* Uncontrolled hypothyroidism (TSH \> 4.5)~* HIV viral load \> 5,000 copies/ml (cpm),~* Active liver disease and/or liver transaminases greater than 2.0 X upper limit of normal~* Active kidney disease or serum creatinine \> 2.5 mg/dL~* Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure~* Uncontrolled hypertension within 4 weeks of study entry (SBP \> 180 mmHg or DBP \> 100 mmHg)~* Use of systemic cancer chemotherapy within 8 weeks of study entry~* Pregnancy or breastfeeding~* Drug or alcohol dependence, or other conditions which may affect study compliance~* History of coagulopathy or use of anticoagulants such as warfarin~* Use of omega-3 fatty acid preparation in the 12 weeks prior to randomization~* Significant changes in clinical status from the Screening Visit which would preclude the patient from being an appropriate candidate.~* Any of the following laboratory parameters: hematocrit \< 25%, absolute neutrophil count \< 1.5 x 10\^9/L, platelets \< 100 x 10\^9/L or hemoglobin \< 8.0 gm/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LOVAZA (Type: EXPERIMENTAL): 4 g/d of omega-3 fatty acid esters, plus dietary counseling
- Placebo (Type: PLACEBO_COMPARATOR): Corn oil placebo, plus dietary counselling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or above~* Life Expectancy \> 3 months~* Histologically confirmed diagnosis of PTCL~* Patients with transformed CTCL eligible for CHOP regimen~* Measurable disease based on Cheson 2007 criteria~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~Exclusion Criteria:~* Known active Hepatitis B/ Hepatitis C/ HIV infection~* Known, uncontrolled CNS metastases or primary CNS lymphoma~* Deep vein thrombosis diagnosed within 3 months~* Ongoing treatment for pre-existing cardiovascular disease~* Neuropathy Grade 3 or more~* Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation~* Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation~* Prior therapy with HDAC inhibitors (except for CTCL)~* Inadequate hematological, hepatic, or renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Finding Phase (Type: EXPERIMENTAL): This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with mild to moderate atopic dermatitis, 2-17 years of age, that agree to participate and provide written consent (and assent if applicable)~* Have an investigator Global Assessment of mild to moderate atopic dermatitis (IGA rating of 2-3 in the Investigator Global Assessment)~* Percentage of overall body surface area of involvement (BSA) must be \> 1% and may include facial and intertriginous skin.~Exclusion Criteria:~* Use within 4 weeks of baseline of systemic anti-inflammatory medication, which may influence study outcome, such as systemic corticosteroids.~* Application or use within 2 weeks of baseline of topical corticosteroid medications or topical anti-inflammatory medication, which may influence study outcome.~* Presence of a concurrent medical condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments.~* Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating int he study (oral antihistamines will be allowed, so long as they are neither initiated nor discontinued during the course of this study)~* Amount of disease involvement that would require \>60gm of cream in a 1 week period~* Subjects with known allergy or sensitivity to Aquaphor Healing Ointment, Atopiclair or EpiCeram or components therein.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aquaphor Healing Ointment (Type: EXPERIMENTAL): Aquaphor Healing Ointment three times daily to atopic dermatitis
- Atopiclair Nonsteroidal Cream (Type: ACTIVE_COMPARATOR): Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
- EpiCream Skin Barrier Emulsion (Type: ACTIVE_COMPARATOR): EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Interferon treatment naive subjects with chronic hepatitis C, HCV genotype 1.~* Compensated liver disease~Key Exclusion Criteria:~* Pregnant or lactating female or males with a pregnant partner.~* A positive test for serum antibodies to the human immunodeficiency virus (HIV-1) or serum hepatitis B virus surface antigen (HBsAg).~* A history of moderate, severe or uncontrolled psychiatric disease.~* A history of immunologically mediated disease, seizure disorder, chronic cardiac disease, chronic pulmonary disease, hemoglobinopathy, coagulopathy, or malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed diagnosis of Type2 diabetes mellitus (T2DM) by standard criteria~* C-peptide \>0.6 ng/ml (\>0.20 nmol/L).~* HbA1c ≥7.5 to ≤11% at Visit 1~* Treatment with stable, once or twice daily doses (maximum dose of \< 1 unit/kg/day) of basal (long-acting, intermediate-acting) insulin alone or pre-mixed insulin for at least 12 weeks prior to Visit 1. Stable is defined as ±10% of the Visit 1 dose during the previous 12 weeks~* Patients receiving metformin must be on a stable dose of metformin (at least 1500 mg daily or a maximally tolerated dose) for at least 12 weeks prior to Visit 1~* Body Mass Index (BMI) ≥20 to ≤40 kg/m2 at Visit~Exclusion Criteria:~Patients fulfilling any of the following criteria are not eligible for participation in the study~* Fasting plasma glucose (FPG) ≥240 mg/dl (13.3 mmol/L) at Visit 1~* Pregnant or lactating women~* Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months~* Current diagnosis of congestive heart failure (NYHA III or IV).~* Myocardial infarction (MI) within the past 6 months~* Liver disease such as cirrhosis or chronic active hepatitis~Other protocol defined inclusion/excusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Therapy for Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>= 18 years)~* Aneurysmal subarachnoid hemorrhage~Exclusion Criteria:~* Uncontrolled systemic hypertension (systolic blood pressure \> 220 mmHg)~* Erythrocytosis vera~* Concurrent erythropoietin therapy~* Negative angiography~* Subarachnoid hemorrhage more than 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male factor infertility~* normal female hormonal profile~* normal uterine cavity~Exclusion Criteria:~* previous ICSI failure~* endometriosis~* azoospermia

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- intrauterine hCG (Type: EXPERIMENTAL): Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Symbicort on GR Localisation in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild steroid-naïve asthma (ATS criteria) of either sex with FEV1 \>70 % pred~* Able to produce sputum after sputum induction~* Exhaled NO (flow 50 ml/s) ≥ 20 ppb~* Written informed consent~Exclusion Criteria:~* Current upper respiratory tract infections~* Use of inhaled and/or oral GCS within 4 weeks prior to visit 1~* Treatment with antileukotrienes, theophylline, tiotropium and ipratropium within 2 weeks prior to screening visit~* Hypersensitivity to any of the investigational drugs or lactose~* Use of any beta blocking agent (including eye-drops)~* Women who are pregnant, breast-feeding or planning a pregnancy during the study. Women must be postmenopausal (at least one year must have passed after the last menstruation), surgically sterile or using acceptable contraceptives, as judged by the investigator~* Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study~* Inability to tolerate temporary withdrawal of bronchodilatory therapy~* Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason~* Previous randomization in this study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo
- Formoterol (Type: EXPERIMENTAL): Oxis(®) 12 μg
- Budesonide low dose (Type: EXPERIMENTAL): Pulmicort(®) 200 μg
- Budesonide high dose (Type: EXPERIMENTAL): Pulmicort(®) 800 μg
- Budesonide/formoterol combination single (Type: EXPERIMENTAL): single 100/6 μg SYM100
- Budesonide/formoterol combination double (Type: EXPERIMENTAL): double 200/12 μg SYM200

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 diabetes~* Patients should be drug naïve ie, not received medical treatment for diabetes~* HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)~Exclusion Criteria:~* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)~* Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Saxagliptin
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas~  * Locally advanced or metastatic disease not amenable to curative surgical resection~ * Macroscopic residual disease after prior resection with histological confirmation is allowed~* Unidimensionally measurable disease~* No intracerebral metastases or meningeal carcinomatosis~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* WHO 0-2~Life expectancy:~* More than 3 months~Hematopoietic:~* WBC greater than 3,000/mm3~* Neutrophil count greater than 1,500/mm3~* Platelet count greater than 100,000/mm3~Hepatic:~* Bilirubin less than 2 mg/dL~Renal:~* Creatinine less than 2 mg/dL~* Creatinine clearance greater than 50 mL/min~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No uncontrolled angina pectoris~Other:~* No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other concurrent uncontrolled medical condition~* No other medical or psychiatric condition that would preclude study~* No known hypersensitivity to fluorouracil~* No dihydropyrimidine dehydrogenase deficiency~* No known malabsorption syndromes~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy (including preoperative or adjuvant) for this disease~* No other concurrent cytotoxic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy (including preoperative or adjuvant) for this disease~Surgery:~* See Disease Characteristics~Other:~* No prior investigational drugs (including preoperative or adjuvant) for this disease~* No other concurrent investigational drugs~* No concurrent dipyridamole or allopurinol~* No concurrent sorivudine or sorivudine analogs (e.g., brivudine) (capecitabine arm only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MMR Vaccination Among HIV-infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For HIV-infected participants, inclusions criteria were~1. 20-59 years old, ability to provide informed consent~2. receiving cART~3. CD4 cell count ≥200 cell/mm3 within 6 months before enrollment~4. plasma HIV-1 RNA \<50 copies/mL, and 5) ability to provide informed consent.~Exclusion Criteria:~For both groups~1. pregnancy or lactating~2. receiving cancer treatment, organ transplantation, ≥0.5 mg/kg/day of prednisolone or equivalent, or immunomodulating treatment~3. impaired renal function (creatinine clearance \<30 mL/min)~4. impaired liver function as defined by Child-Pugh C.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- HIV-infected adults (Type: ACTIVE_COMPARATOR): Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains.
- HIV-uninfected adults (Type: EXPERIMENTAL): Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Hepatic Hemodynamics During Liver Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients within ASA-class I-II scheduled for open liver resection~Exclusion Criteria:~* ASA-class III and IV, more than 2 medications for hypertension, BMI \> 35, technical difficulties with insertion av catheters, extensive surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vasopressin + nitro (Type: EXPERIMENTAL): vasopressin + nitroglycerin in simultaneous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete